SCHEMBL7025952

SCHEMBL7025952

COc1cc(CO)c(C2=CCN(C)CC2)c(O)c1C(=O)/C=C/c1cccc([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 5/20 0.54
TXNRD1 Q16881 1/20 0.54
TXNRD3 Q86VQ6 1/20 0.54
TXNRD2 Q9NNW7 1/20 0.54
MAPT P10636 5/20 0.44
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TRPV1 Q8NER1 1/20 0.42
USP2 O75604 1/20 0.42
POLB P06746 1/20 0.42
RECQL P46063 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.41
ACHE P22303 1/20 0.41
HSP90AA1 P07900 1/20 0.41
CCR6 P51684 1/20 0.41
ITGB2 P05107 1/20 0.41
ICAM1 P05362 1/20 0.41
ITGAL P20701 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL746105 0.92 ABCB1 (0.57) ABCB1TXNRD1TXNRD3TXNRD2MAPT
SCHEMBL20859001 0.91 TXNRD1 (0.55) ABCB1TXNRD1TXNRD3TXNRD2MAPT
SCHEMBL7029021 0.89 ABCB1 (0.46) ABCB1MAPTNPSR1
SCHEMBL7028079 0.88 ABCG2 (0.51) ABCB1MAPTNPSR1MAOB
SCHEMBL7026486 0.88 MAPT (0.53) ABCB1MAPTNPSR1MAOB
SCHEMBL7025976 0.87 ABCB1 (0.51) ABCB1MAPTNPSR1MAOB
SCHEMBL7025959 0.87 AR (0.46) ABCB1MAPTALDH1A1POLBNPSR1
SCHEMBL7027366 0.84 PDPK1 (0.47) ABCB1MAPTNPSR1LMNAMAOB
SCHEMBL7028113 0.84 MAPT (0.43) ABCB1MAPTNPSR1
SCHEMBL7030660 0.83 TDP1 (0.50) ABCB1MAPTALDH1A1RECQLNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER SHANDONG UNIVERSITY (CN) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER CDK6, CDK5, CDK4 ABCB1 2307/4885TXNRD1 1276/4885TXNRD3 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.